Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) will announce its fourth quarter and full-year 2020 financial results on February 25, 2021, at 8 a.m. ET. The company focuses on developing curative therapeutics utilizing CRISPR/Cas9 technology for both in vivo and ex vivo applications. Interested participants can join the conference call by dialing the provided numbers. A replay of the call will be available later that day on the company's website. Intellia's mission is to produce permanent gene edits and engineered cells to treat various diseases.

Positive

• Focus on developing potentially curative therapeutics using CRISPR/Cas9 technology.
• Announcement of upcoming financial results may signify operational transparency.

Negative

• None.

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.

To join the call:

• U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.
• All participants should ask to be connected to the Intellia Therapeutics conference call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on February 25, 2021 at 12 p.m. ET.

About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products. Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Follow us on Twitter @intelliatweets.

Intellia Contacts:

Investors:
Glenn Goddard
Chief Financial Officer
+1-857-706-1056
glenn.goddard@intelliatx.com

Media:
Julie Ferguson
Interim Head of External Affairs & Communications
+1-312-385-0098
julie.ferguson@intelliatx.com

FAQ

When will Intellia Therapeutics announce its fourth quarter and full-year 2020 financial results?

Intellia Therapeutics will announce its financial results on February 25, 2021, at 8 a.m. ET.

How can I join the Intellia Therapeutics conference call?

U.S. callers can dial 1-833-316-0545 and international callers should dial 1-412-317-5726, about five minutes before the call.

Where can I find the replay of the Intellia Therapeutics conference call?

The replay will be available on the Events and Presentations page of Intellia's website starting February 25, 2021, at 12 p.m. ET.

What is Intellia Therapeutics' main focus?

Intellia Therapeutics focuses on developing curative therapeutics using the CRISPR/Cas9 genome editing technology.

What technology does Intellia Therapeutics use for its therapeutics?

Intellia Therapeutics uses CRISPR/Cas9 technology for developing its therapeutics.